Talphera Inc - Company Profile
Powered by 
All the sales intelligence you need on Talphera Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Talphera Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Talphera Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Talphera Inc (Talphera), formerly AcelRx Pharmaceuticals Inc, is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings. The company's main activities revolve around the development of Niyad, a regional anticoagulant for the dialysis circuit, and LTX-608, a nafamostat formulation for direct IV infusion. Talphera's product portfolio includes Niyad, which is designed for continuous renal replacement therapy in acute kidney injury patients, and LTX-608, which is being explored for treating conditions such as disseminated intravascular coagulation and acute respiratory distress syndrome. The company's products are primarily targeted at healthcare providers and are used in acute care settings. Talphera is evaluating its distribution strategies as it prioritizes its nafamostat-based therapies. Talphera is headquartered in San Mateo, California, the US.
Headquarters
United States of America
Address
Suite 175, 1850 Gateway Drive, San Mateo, California, 94404
Website
talphera.com
Telephone
1 650 2163500
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TLPH (NASD)
Revenue (2024)
$28,000
EPS
XYZ
Net Income (2024)
XYZ
-9.9%
(2024 vs 2023)
Market Cap*
$62.3M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Talphera Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Niyad |
| LTX-608 |
Competitor Comparison
| Key Parameters | Talphera Inc | Biogen Inc | UCB SA | Grifols SA | ADMA Biologics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Belgium | Spain | United States of America |
| City | San Mateo | Cambridge | Anderlecht | Sant Cugat Del Valles | Ramsey |
| State/Province | California | Massachusetts | Bruxelles-Capitale | Barcelona | New Jersey |
| No. of Employees | 12 | 7,500 | 10,117 | 23,822 | 647 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Adrian Adams | Chairman | Executive Board | 2013 | 75 |
| Vincent J. Angotti | Chief Executive Officer; Director | Executive Board | 2017 | 58 |
| Raffi Asadorian | Chief Financial Officer | Senior Management | 2017 | 56 |
| Shakil Aslam | Chief Medical Officer | Senior Management | - | 62 |
| Badri Dasu | Chief Engineering Officer | Senior Management | 2007 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer